Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC

Inclusion Criteria:

1. Subject is at least 18 years of age

2. Subject has diagnosed Type 1 or Type 2 diabetes

3. Subject's wound is located on foot or ankle (DFU) or leg (VLU)

4. Subject has diabetic foot ulcer > 1.0 cm2 and ≤ 25 cm2 OR venous leg ulcer > 1.0 cm2and ≤ 50 cm2

5. Subject has adequate circulation to affected extremity with TcPO2 results of ≥ 40 mmHg on the dorsum of the affected foot or ABI results ≥ 0.7 and≤ 1.2 or Great ToePressure ≥ 50 mmHg

6. Subject is willing and able to comply with all protocol requirements

7. Subject is willing and able to provide informed consent or obtain consent from legalauthorized representative (LAR)

Exclusion Criteria:

1. Subject is pregnant

2. Subject has HbA1C > 12 within 3 months Prior to randomization

3. Subject has > 30% reduction in wound size after 2-week run-in period

4. Subject has active infection, undrained abscess, or critical colonization of thewound with bacteria

5. Subject has osteomyelitis or exposed bones, probes to bone or joint capsule oninvestigator's exam or radiographic evidence or bone culture, histology, x-raychanges or MRI

6. Subject is on parenteral corticosteroids or any cytotoxic agents for 7 consecutivedays during 30 days before screening. Chronic oral steroid use is not excluded ifdose < 10 mg per day of prednisone

7. Subject is currently undergoing cancer treatment

8. Subject has used biologic skin substitutes within 14 days of enrollment

9. Subject has an allergy to suture material

10. Subject has life expectancy less than six-months as assessed by the investigator

11. Subject is participating in another clinical research study prior to this studycompletion